甘李药业：子公司产品获得欧盟上市许可

Core Viewpoint - The company has received marketing authorization for its long-acting insulin product, Ondibta®, in the EU and select European countries, which is expected to enhance its international market presence [1] Group 1: Product Approval - The company's European subsidiary has been granted marketing authorization by the European Commission for Ondibta®, a long-acting insulin injection [1] - Ondibta® is indicated for the treatment of diabetes in adults, adolescents, and children aged 2 years and older [1] - The product provides a stable blood concentration and maintains blood sugar control for up to 24 hours [1] Group 2: Market Expansion - The approval is a significant step for the company in expanding its international market footprint [1] - Future sales of the product may be influenced by market demand, regulatory environment, currency fluctuations, and competition [1]